Merck Investments Non Current vs Investments Current Analysis

MRK Stock  USD 131.75  6.23  4.96%   
Trend analysis of Merck Company balance sheet accounts such as Total Current Liabilities of 13.3 B provides information on Merck's total assets, liabilities, and equity, which is the actual value of Merck Company to its prevalent stockholders. By breaking down trends over time using Merck balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
  
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Merck Company. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

About Merck Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Merck Company at a specified time, usually calculated after every quarter, six months, or one year. Merck Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Merck and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Merck currently owns. An asset can also be divided into two categories, current and non-current.

Merck Balance Sheet Chart

Merck Balance Sheet is one of the main financial statements that report all assets, liabilities, and shareholders' equity for the current year. It provides a basis for different types of computing rates of return, such as return on equity (ROE) or return on asset (ROA), as well as shows how Merck Company uses and utilizes its capital. It also shows what exactly a company owns and owes.
At this time, Merck's Net Receivables is quite stable compared to the past year. Common Stock Shares Outstanding is expected to rise to about 2.7 B this year, although the value of Total Stockholder Equity will most likely fall to about 25.5 B.

Total Assets

Total assets refers to the total amount of Merck assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Merck Company books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Merck balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Merck Company are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.
Most indicators from Merck's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Merck Company current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Merck Company. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.
Enterprise Value Multiple is expected to rise to 46.87 this year, although the value of Selling General Administrative will most likely fall to about 8.9 B.
 2021 2022 2023 2024 (projected)
Gross Profit35.1B41.9B43.9B46.1B
Total Revenue48.7B59.3B59.9B32.5B

Merck fundamental ratios Correlations

0.570.720.790.870.530.280.880.731.00.220.740.610.30.740.930.590.150.70.980.30.80.490.270.950.16
0.570.920.750.250.890.910.750.20.590.690.110.9-0.270.950.580.95-0.550.970.50.270.240.760.750.64-0.24
0.720.920.850.420.810.780.90.350.740.570.310.84-0.190.940.710.89-0.460.960.670.30.40.820.640.77-0.1
0.790.750.850.40.610.60.930.420.810.640.280.63-0.250.770.860.68-0.430.820.730.520.370.860.40.87-0.17
0.870.250.420.40.33-0.070.590.790.84-0.170.90.430.670.470.720.360.570.40.90.080.930.050.10.720.37
0.530.890.810.610.330.740.650.330.530.70.130.98-0.140.840.570.93-0.360.870.50.150.390.620.890.53-0.4
0.280.910.780.6-0.070.740.57-0.210.330.65-0.220.75-0.510.80.280.84-0.730.830.180.11-0.090.730.710.41-0.2
0.880.750.90.930.590.650.570.480.890.490.450.69-0.140.820.840.76-0.310.830.840.260.50.80.480.90.01
0.730.20.350.420.790.33-0.210.480.690.10.80.350.540.380.750.240.440.350.80.410.810.110.070.6-0.08
1.00.590.740.810.840.530.330.890.690.250.690.620.260.760.920.60.110.720.960.30.790.530.280.950.13
0.220.690.570.64-0.170.70.650.490.10.25-0.340.62-0.630.530.40.63-0.720.610.160.36-0.090.80.710.3-0.76
0.740.110.310.280.90.13-0.220.450.80.69-0.340.210.740.340.630.170.610.280.830.20.79-0.1-0.160.620.52
0.610.90.840.630.430.980.750.690.350.620.620.21-0.040.90.620.93-0.290.910.570.130.470.60.830.62-0.28
0.3-0.27-0.19-0.250.67-0.14-0.51-0.140.540.26-0.630.74-0.04-0.050.23-0.20.92-0.120.380.080.67-0.61-0.380.190.47
0.740.950.940.770.470.840.80.820.380.760.530.340.9-0.050.710.9-0.340.990.680.270.470.70.630.79-0.1
0.930.580.710.860.720.570.280.840.750.920.40.630.620.230.710.550.030.720.920.530.720.570.250.94-0.05
0.590.950.890.680.360.930.840.760.240.60.630.170.93-0.20.90.55-0.430.920.540.130.340.690.860.59-0.19
0.15-0.55-0.46-0.430.57-0.36-0.73-0.310.440.11-0.720.61-0.290.92-0.340.03-0.43-0.420.23-0.120.57-0.74-0.48-0.030.46
0.70.970.960.820.40.870.830.830.350.720.610.280.91-0.120.990.720.92-0.420.640.350.40.750.660.77-0.17
0.980.50.670.730.90.50.180.840.80.960.160.830.570.380.680.920.540.230.640.310.820.40.220.910.21
0.30.270.30.520.080.150.110.260.410.30.360.20.130.080.270.530.13-0.120.350.310.120.3-0.160.41-0.27
0.80.240.40.370.930.39-0.090.50.810.79-0.090.790.470.670.470.720.340.570.40.820.120.070.160.650.15
0.490.760.820.860.050.620.730.80.110.530.8-0.10.6-0.610.70.570.69-0.740.750.40.30.070.570.58-0.37
0.270.750.640.40.10.890.710.480.070.280.71-0.160.83-0.380.630.250.86-0.480.660.22-0.160.160.570.22-0.48
0.950.640.770.870.720.530.410.90.60.950.30.620.620.190.790.940.59-0.030.770.910.410.650.580.220.14
0.16-0.24-0.1-0.170.37-0.4-0.20.01-0.080.13-0.760.52-0.280.47-0.1-0.05-0.190.46-0.170.21-0.270.15-0.37-0.480.14
Click cells to compare fundamentals

Merck Account Relationship Matchups

Merck fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets84.4B91.6B105.7B109.2B106.7B60.3B
Short Long Term Debt Total26.3B31.8B33.1B30.7B36.3B38.1B
Other Current Liab14.9B16.3B16.9B18.0B15.5B16.3B
Total Current Liabilities22.2B27.3B23.9B24.2B25.7B13.3B
Total Stockholder Equity25.9B25.3B38.2B46.0B37.6B25.5B
Property Plant And Equipment Net15.1B18.0B19.3B21.4B24.5B25.7B
Net Debt16.7B23.7B25.0B18.0B29.4B30.8B
Retained Earnings46.6B47.4B53.7B61.1B53.9B32.6B
Cash9.7B8.1B8.1B12.7B6.9B5.6B
Non Current Assets Total56.9B63.8B75.4B73.4B74.5B41.1B
Non Currrent Assets Other5.3B9.2B8.1B7.7B9.2B6.1B
Cash And Short Term Investments10.5B8.1B8.1B13.2B7.2B7.3B
Net Receivables6.8B7.9B9.2B9.5B11.1B11.6B
Common Stock Shares Outstanding2.6B2.5B2.5B2.5B2.5B2.7B
Liabilities And Stockholders Equity84.4B91.6B105.7B109.2B106.7B60.3B
Non Current Liabilities Total36.2B38.9B43.6B38.9B43.3B45.5B
Inventory6.0B6.3B6.0B5.9B6.4B3.7B
Other Current Assets4.3B5.5B7.0B7.2B7.6B8.0B
Other Stockholder Equity(16.3B)(17.2B)(12.9B)(12.1B)(12.9B)(12.3B)
Total Liab58.4B66.2B67.4B63.1B69.0B72.5B
Total Current Assets27.5B27.8B30.3B35.7B32.2B19.2B
Short Term Debt3.6B6.4B2.4B1.9B1.7B2.3B
Intangible Assets14.2B14.6B22.9B20.3B18.0B14.3B
Accounts Payable3.7B4.6B4.6B4.3B3.9B2.8B
Property Plant And Equipment Gross15.1B18.0B37.5B39.4B41.3B43.4B
Accumulated Other Comprehensive Income(6.2B)(6.6B)(4.4B)(4.8B)(5.2B)(4.9B)
Short Term Investments774M1M0.0498M252M239.4M
Other Liab12.7B12.1B11.7B9.1B10.5B10.2B
Other Assets5.3B7.8B9.4B7.4B8.5B5.5B
Long Term Debt22.7B25.4B30.7B28.7B33.7B17.2B
Good Will19.4B20.2B21.3B21.2B21.2B12.3B
Treasury Stock(50.9B)(56.0B)(56.8B)(57.1B)(51.4B)(54.0B)
Property Plant Equipment15.1B18.0B19.3B21.4B24.6B16.2B
Net Tangible Assets(7.7B)(9.5B)3.5B4.5B4.1B4.5B
Noncontrolling Interest In Consolidated Entity94M87M73M67M60.3M57.3M
Retained Earnings Total Equity46.6B47.4B53.7B61.1B70.2B46.0B

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Merck Company is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Merck Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Merck Company Stock. Highlighted below are key reports to facilitate an investment decision about Merck Company Stock:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Merck Company. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.
You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.

Complementary Tools for Merck Stock analysis

When running Merck's price analysis, check to measure Merck's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Merck is operating at the current time. Most of Merck's value examination focuses on studying past and present price action to predict the probability of Merck's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Merck's price. Additionally, you may evaluate how the addition of Merck to your portfolios can decrease your overall portfolio volatility.
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Is Merck's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Merck. If investors know Merck will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Merck listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.453
Dividend Share
2.92
Earnings Share
0.14
Revenue Per Share
23.695
Quarterly Revenue Growth
0.058
The market value of Merck Company is measured differently than its book value, which is the value of Merck that is recorded on the company's balance sheet. Investors also form their own opinion of Merck's value that differs from its market value or its book value, called intrinsic value, which is Merck's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Merck's market value can be influenced by many factors that don't directly affect Merck's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Merck's value and its price as these two are different measures arrived at by different means. Investors typically determine if Merck is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Merck's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.